AA
AMAM

ALPS Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

ALPS Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-45,531
Closed -$524K – 1021
2023
Q3 		$524K Buy
45,531
+4,933
+12% +$67.2K ﹤0.01% 592
2023
Q2 		$668K Buy
+40,598
New +$510K 0.01% 559

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ALPS Advisors's AMAM Position: Q4 2023 in Review

ALPS Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q4 2023, closing a stake of 45,531 shares — an estimated $524K sold.

ALPS Advisors first reported a position in AMAM in Q2 2023 and held it in 2 quarters. The position peaked at $668K in Q2 2023. 68 funds tracked by Wall St. Rank hold AMAM as of Q4 2023.

  • ALPS Advisors reported no remaining Ambrx Biopharma Inc position as of Q4 2023 after selling out during the quarter.
  • ALPS Advisors sold 45,531 Ambrx Biopharma Inc shares in Q4 2023, an estimated $524K.
  • ALPS Advisors first reported a position in Ambrx Biopharma Inc in Q2 2023 and held it in 2 quarters.
  • ALPS Advisors's Ambrx Biopharma Inc position peaked at $668K in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.